Metformin monotherapy versus predominantly older non‐metformin antidiabetic medications for cerebrovascular risk in early type 2 diabetes management
Main finding · Overall cerebrovascular diseasesResult — go to the resultAdjusted hazard ratio 0.67-0.69Authors' conclusion
Metformin monotherapy is associated with a reduced risk of cerebrovascular diseases in early-stage T2D, highlighting its dose-dependent efficacy. However, the observed benefits might also be influenced by baseline differences and the increased risks associated with other medications, such as sulphonylureas. These findings emphasize the need for personalized diabetes management, particularly in mitigating cerebrovascular risk in early T2D stages.
Study context
- Population
- Patients with T2D without diabetic complications starting first-line monotherapy
- Participants
- 9,090 patients
- Exposure
- Metformin monotherapy vs non-metformin antidiabetic medications as first-line therapy
- Outcome
- Cerebrovascular diseases
Methodological detailscompeting risk analysis
- Competing risk analysis
Main finding
Overall cerebrovascular diseases
Adjusted hazard ratio
0.67-0.69
As reported in the abstract
- Significantly lower crude incidence of cerebrovascular diseases with metformin vs non-users
- P < 0.0001
Observational data: associations, not effects.
Further findings
| Outcome | aHR |
|---|---|
| Severe cerebrovascular eventsRange across models | 0.67-0.69 |
| Mild cerebrovascular diseasesSignificant across all models | 0.73-0.74 |
Cerebrovascular risk by cumulative defined daily doses of metformin
- Higher cumulative defined daily doses correlated with reduced cerebrovascular risk (IRR), dose-dependent effect
- 0.62-0.94, p < .0001
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →